AZTherapies
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Clarendon St Fl 17, Boston, Massachu...Phone Number
(617) 318-3411Website
www.aztherapies.comRevenue
$10.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About AZTherapies
AZTherapies is an advanced clinical-stage bio-pharmaceutical company developing novel therapies that aim to fundamentally change neuro-degenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. The company was established in 2011 and is headquartered out of Boston, MA.Explore more
AZTherapies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AZTherapies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if AZTherapies had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at AZTherapies
Check out if AZTherapies is spiking on competitors!
Product Launch: Get notified when AZTherapies launches new products
AZTherapies, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on AZTherapies recently announced quarterly report
Funding: Get notified immidiatlly once AZTherapies has new funding data
Check if AZTherapies has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to AZTherapies
Compare insights from companies similar to AZTherapies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AZTherapies is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AZTherapies is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AZTherapies.
AZTherapies financials insights
Gather financial insights about AZTherapies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$6.1M
2015
Private Equity
$16.1M
Series A
$16.5M
2017
Angel/Seed
$6.5M
Debt
$1.6M
2018
Series B
$23.8M
2020
Debt
$350K
Series C
$37.5M
2021
Debt
$787K
AZTherapies Tech Stack
A closer look at the technologies used by AZTherapies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Funding
AZTherapies has received an SBA PPP loan in the amount of $787,960 from Bank of America resulting in the retention of 27 jobs.
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire
AZTherapies News & Media
AZTherapies Announces Leadership Transition, Appointing Marc de Garidel Chief Executive Officer and Member of the Board of Directors
Company founder David R. Elmaleh, Ph.D., remains Executive Chairman of the Board and Chief Scientific Officer Company founder David R. Elmaleh, Ph.D., remains Executive Chairman of the Board and Chief Scientific OfficerAZTherapies Announces Closing of $33.6 Million Series C-1 Financing Building Upon Recent $37.5 Million Series C Financing
Proceeds will help AZTherapies expand regulatory and pre-commercial activities related to Phase 3 candidate for early Alzheimer’s disease and advance other neuroinflammation-targeted programs Proceeds will help AZTherapies expand regulatory and pre-commercial activities related to Phase 3 candidate for early Alzheimer’s disease and advance other neuroinflammation-targeted programsAZTherapies Doses First Patient in Phase 2a Study of ALZT-OP1a in Amyotrophic Lateral Sclerosis (ALS)
Randomized, open-label, multi-center, dose optimization study expected to evaluate 80 patients with mild- to moderate-stage ALS Randomized, open-label, multi-center, dose optimization study expected to evaluate 80 patients with mild- to moderate-stage ALS
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AZTherapies
Sign Up For FreeTo access detailed company insights
AZTherapies is an advanced clinical-stage bio-pharmaceutical company developing novel therapies that aim to fundamentally change neuro-degenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. The company was established in 2011 and is headquartered out of Boston, MA.... Read More
